Evidence map›Paper›PMID 36348405›Full record

ArticleJournal of translational medicine2022

Promotion of a synthetic degradation of activated STAT6 by PARP-1 inhibition: roles of poly(ADP-ribosyl)ation, calpains and autophagy.

Jeffrey Wang, Mohamed A Ghonim, Salome V Ibba, Hanh H Luu, Yucel Aydin, Peter A Greer, A Hamid Boulares

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jeffrey Wang *School of Medicine, The Stanley Scott Cancer Center/Louisiana Cancer Research Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Mohamed A Ghonim *School of Medicine, The Stanley Scott Cancer Center/Louisiana Cancer Research Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Salome V IbbaSchool of Medicine, The Stanley Scott Cancer Center/Louisiana Cancer Research Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Hanh H LuuSchool of Medicine, The Stanley Scott Cancer Center/Louisiana Cancer Research Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Yucel AydinDepartment of Pathology and Laboratory Sciences, Tulane University Health Science Center, New Orleans, USA.
Peter A GreerDivision of Cancer Biology and Genetics, Cancer Research Institute, Kingston, ON, Canada.
A Hamid BoularesSchool of Medicine, The Stanley Scott Cancer Center/Louisiana Cancer Research Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA. hboulr@lsuhsc.edu.ORCID 0000-0001-9916-8126
Louisiana Cancer Research Center · USAl-Azhar University · EGTulane University · US

Funding

Vascular and Cardiac Function Core - "Mentoring in Cardiovascular BiologyP30GM106392 · NIGMS · LSU HEALTH SCIENCES CENTER · PI KAPUSTA, DANIEL R · 2014 to 2018
$5.5M
Translational Genomics CoreP30GM114732 · NIGMS · LSU HEALTH SCIENCES CENTER · PI OCHOA, AUGUSTO C. · 2015 to 2019
$5.2M
Understanding and Addressing Cancer Health Disparities in LouisianaP20CA233374 · NCI · LSU HEALTH SCIENCES CENTER · PI MIELE, LUCIO · 2018 to 2020
$2.9M
American Heart Association-American Stroke Association 17CPRE33660741NCI NIH HHS P20 CA233374NIGMS NIH HHS P30 GM106392NIGMS NIH HHS P30 GM114732NIH HHS P20CA233374NIH HHS P30GM114732
6 · The paper itself

Abstract

backgroundWe reported that PARP-1 regulates genes whose products are crucial for asthma, in part, by controlling STAT6 integrity speculatively through a calpain-dependent mechanism. We wished to decipher the PARP-1/STAT6 relationship in the context of intracellular trafficking and promoter occupancy of the transcription factor on target genes, its integrity in the presence of calpains, and its connection to autophagy.

methodsThis study was conducted using primary splenocytes or fibroblasts derived from wild-type or PARP-1

resultsWe show that the role for PARP-1 in expression of IL-4-induced genes (e.g. gata-3) in splenocytes did not involve effects on STAT6 phosphorylation or its subcellular trafficking, rather, it influenced its occupancy of gata-3 proximal and distal promoters in the early stages of IL-4 stimulation. At later stages, PARP-1 was crucial for STAT6 integrity as its inhibition, pharmacologically or by gene knockout, compromised the fate of the transcription factor. Calpain-1 appeared to preferentially degrade JAK-phosphorylated-STAT6, which was blocked by calpastatin-mediated inhibition or by genetic knockout in mouse fibroblasts. The STAT6/PARP-1 relationship entailed physical interaction and modification by poly(ADP-ribosyl)ation independently of double-strand-DNA breaks. Poly(ADP-ribosyl)ation protected phosphorylated-STAT6 against calpain-1-mediated degradation. Additionally, our results show that STAT6 is a bonafide substrate for chaperone-mediated autophagy in a selective and calpain-dependent manner in the human Jurkat cell-line. The effects were partially blocked by IL-4 treatment and PARP-1 inhibition.

conclusionsThe results demonstrate that poly(ADP-ribosyl)ation plays a critical role in protecting activated STAT6 during Th2 inflammation, which may be synthetically targeted for degradation by inhibiting PARP-1.

Indexed as

Poly(ADP-ribose) PolymerasesPoly ADP RibosylationAnimalsAutophagyCalpainHumansInflammationInterleukin-4MicePoly(ADP-ribose) Polymerase InhibitorsSTAT6 Transcription FactorCalpainInterleukin-4Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesSTAT6 protein, humanStat6 protein, mouseSTAT6 Transcription FactorAutophagyCalpainsOlaparibPARP-1Poly(ADP-ribosyl)ationProtein degradationTh2 inflammationTherapeutics

Identifiers

PMID36348405
PMCPMC9644602
OpenAlexW4308571819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.